Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
401
Recruiting Now
401
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT05320588 Phase 1, Phase 2
Recruiting
A Study in Patients With Advanced Cancers
Condition
Advanced Cancer
Enrollment
332 pts
Location
United States
Sponsor
BiOneCure Therapeutics Inc.
NCT06841042 Phase 1, Phase 2
Recruiting
A Study of SCTB35 in Patients with Systemic Lupus Erythematosus
Condition
System Lupus Erythematosus
Enrollment
168 pts
Location
China
Sponsor
Sinocelltech Ltd.
NCT06141460 Phase 1, Phase 2
Recruiting
Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-rela...
Condition
Neovascular Age-related Macular Degeneration
Enrollment
48 pts
Location
China
Sponsor
Shanghai Refreshgene Technolog
NCT07551362 Phase 1, Phase 2
Recruiting
Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
Condition
Advanced Gastric Adenocarcinoma
Enrollment
36 pts
Location
China
Sponsor
Beijing Biotech
NCT07028073 Phase 1, Phase 2
Recruiting
A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia
Condition
Acute Myeloid Leukemia With T(8;21)(Q22;Q22)
Enrollment
78 pts
Location
China
Sponsor
The First Affiliated Hospital
NCT06554795 Phase 1, Phase 2
Recruiting
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
Condition
Solid Tumor, Adult
Enrollment
360 pts
Location
United States, Australia, China
Sponsor
DualityBio Inc.
NCT07477912 Phase 1, Phase 2
Recruiting
Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple My...
Condition
Multiple Myeloma Refractory
Enrollment
30 pts
Location
Belarus
Sponsor
Minsk Scientific-Practical Cen
NCT03167437 Phase 1, Phase 2
Recruiting
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerat...
Condition
Crohn's Disease
Enrollment
35 pts
Location
United States
Sponsor
National Institute of Allergy
NCT05864053 Phase 1, Phase 2
Recruiting
(2R,6R)-Hydroxynorketamine for the Treatment of Neuropathic Pain
Condition
Pain, Neuropathic
Enrollment
25 pts
Location
United States
Sponsor
Rush University Medical Center
NCT05589753 Phase 1, Phase 2
Recruiting
Sleep Disordered Breathing With Opioid Use
Condition
Sleep Apnea
Enrollment
150 pts
Location
United States
Sponsor
VA Office of Research and Deve
NCT05207657 Phase 1, Phase 2
Recruiting
Lentiviral Gene Therapy for p47 AR-CGD
Condition
P47-Phox, Deficiency of
Enrollment
5 pts
Location
United Kingdom
Sponsor
Great Ormond Street Hospital f
NCT07545265 Phase 1, Phase 2
Recruiting
SKB565 for Injection in Advanced Solid Tumors
Condition
Advanced Solid Tumors
Enrollment
180 pts
Location
China
Sponsor
Sichuan Kelun-Biotech Biopharm
NCT04588922 Phase 1, Phase 2
Recruiting
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Pa...
Condition
Hematologic Malignancies
Enrollment
160 pts
Location
United States, China
Sponsor
Sellas Life Sciences Group
NCT06026657 Phase 1, Phase 2
Recruiting
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer...
Condition
Anatomic Stage IV Breast Cancer AJCC v8
Enrollment
42 pts
Location
United States
Sponsor
Margaret Gatti-Mays
NCT07701941 Phase 1, Phase 2
Recruiting
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deru...
Condition
Hormone Receptor Positive
Enrollment
220 pts
Location
United States, Belgium, France
Sponsor
Daiichi Sankyo
NCT05732831 Phase 1, Phase 2
Recruiting
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Condition
Locally Advanced Solid Tumor
Enrollment
225 pts
Location
United States, France, Spain
Sponsor
Tango Therapeutics, Inc.
NCT07535437 Phase 1, Phase 2
Recruiting
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People Wit...
Condition
Non-Small Cell Lung Cancer
Enrollment
66 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance
NCT07805551 Phase 1, Phase 2
Recruiting
A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer
Condition
CRC, Colorectal Cancer
Enrollment
220 pts
Location
China
Sponsor
Hangzhou Zhongmei Huadong Phar
NCT06902012 Phase 1, Phase 2
Recruiting
Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R L...
Condition
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Enrollment
15 pts
Location
China
Sponsor
Zhujiang Hospital
NCT07341737 Phase 1, Phase 2
Recruiting
SL-28 for Advanced Solid Tumours
Condition
Head & Neck Cancer
Enrollment
60 pts
Location
Australia
Sponsor
Second Life Therapeutics
NCT06012695 Phase 1, Phase 2
Recruiting
NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Gli...
Condition
Malignant Neoplasm
Enrollment
79 pts
Location
Taiwan
Sponsor
Novelwise Pharmaceutical Corpo
NCT07549022 Phase 1, Phase 2
Recruiting
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve She...
Condition
Malignant Peripheral Nerve Sheath Tumors
Enrollment
17 pts
Location
United States
Sponsor
Ankit Mangla, MD
NCT05256745 Phase 1, Phase 2
Recruiting
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
Condition
Cancer Related Cognitive Decline
Enrollment
48 pts
Location
United States
Sponsor
Georgetown University
NCT07266116 Phase 1, Phase 2
Recruiting
Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Inject...
Condition
Systemic Light Chain Amyloidosis
Enrollment
70 pts
Location
China
Sponsor
Shanghai Chia Tai Tianqing Pha
NCT05580458 Phase 1, Phase 2
Recruiting
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in Peopl...
Condition
Herpes Zoster
Enrollment
225 pts
Location
United States
Sponsor
National Institute of Allergy
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology